Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cross-reactivity00:42

Cross-reactivity

33.7K
Overview
33.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Self-reported reactogenicity of RSV vaccines among older adults: a post-licensure study within a large integrated healthcare system in Southern California.

Vaccine·2026
Same author

Navigating power in policy adoption: The political economy of noncommunicable diseases in Sierra Leone.

SSM - health systems·2025
Same author

Health-seeking behaviour, health service delivery and its perceived impact among stroke survivors in Sierra Leone: a longitudinal qualitative study embedded in the SISLE project.

BMC health services research·2025
Same author

Pneumococcal vaccination knowledge, attitudes, and practices among surveyed U.S. adults aged 19-64 years at increased risk for pneumococcal disease.

Vaccine·2025
Same author

Health justice in fragile and shock-prone settings: from theory to practice towards building resilient health systems.

BMJ global health·2025
Same author

A Texting- and Internet-Based Self-Reporting System for Enhanced Vaccine Safety Surveillance With Insights From a Large Integrated Health Care System in the United States: Prospective Cohort Study.

JMIR mHealth and uHealth·2024

Related Experiment Video

Updated: Mar 18, 2026

In Vitro ELISA Test to Evaluate Rabies Vaccine Potency
09:04

In Vitro ELISA Test to Evaluate Rabies Vaccine Potency

Published on: May 11, 2020

13.4K

Implementing an Ebola Vaccine Study - Sierra Leone.

Marc-Alain Widdowson1, Stephanie J Schrag, Rosalind J Carter

  • 1National Center for Immunization and Respiratory Diseases, CDC.

MMWR Supplements
|July 9, 2016
PubMed
Summary

The Sierra Leone Trial to Introduce a Vaccine against Ebola (STRIVE) evaluated the rVSV-ZEBOV vaccine in healthcare workers. The trial found no Ebola cases or serious adverse events, supporting vaccine licensure.

More Related Videos

Modeling The Lifecycle Of Ebola Virus Under Biosafety Level 2 Conditions With Virus-like Particles Containing Tetracistronic Minigenomes
10:11

Modeling The Lifecycle Of Ebola Virus Under Biosafety Level 2 Conditions With Virus-like Particles Containing Tetracistronic Minigenomes

Published on: September 27, 2014

37.1K
Unbiased Deep Sequencing of RNA Viruses from Clinical Samples
09:36

Unbiased Deep Sequencing of RNA Viruses from Clinical Samples

Published on: July 2, 2016

17.8K

Related Experiment Videos

Last Updated: Mar 18, 2026

In Vitro ELISA Test to Evaluate Rabies Vaccine Potency
09:04

In Vitro ELISA Test to Evaluate Rabies Vaccine Potency

Published on: May 11, 2020

13.4K
Modeling The Lifecycle Of Ebola Virus Under Biosafety Level 2 Conditions With Virus-like Particles Containing Tetracistronic Minigenomes
10:11

Modeling The Lifecycle Of Ebola Virus Under Biosafety Level 2 Conditions With Virus-like Particles Containing Tetracistronic Minigenomes

Published on: September 27, 2014

37.1K
Unbiased Deep Sequencing of RNA Viruses from Clinical Samples
09:36

Unbiased Deep Sequencing of RNA Viruses from Clinical Samples

Published on: July 2, 2016

17.8K

Area of Science:

  • * Global Health Security
  • * Vaccinology
  • * Infectious Disease Epidemiology

Background:

  • * The 2014 Ebola epidemic highlighted the urgent need for effective vaccines.
  • * Accelerating vaccine assessment and availability was a global priority.
  • * Sierra Leone was heavily impacted, necessitating local research capacity.

Purpose of the Study:

  • * To evaluate the efficacy, immunogenicity, and safety of the recombinant vesicular stomatitis virus Ebola vaccine (rVSV-ZEBOV).
  • * To assess the feasibility of conducting a large-scale vaccine trial during a public health emergency.
  • * To support regulatory decisions for the rVSV-ZEBOV vaccine licensure.

Main Methods:

  • * Individually randomized controlled phase II/III trial involving healthcare and frontline workers.
  • * Participants received either immediate or delayed vaccination with rVSV-ZEBOV.
  • * Monthly follow-up for 6 months post-vaccination, with substudies for reactogenicity and immunogenicity.

Main Results:

  • * 8,673 participants enrolled between April and August 2015.
  • * No Ebola cases were reported in the study population by April 2016.
  • * No vaccine-related serious adverse events were reported.

Conclusions:

  • * The STRIVE trial demonstrated the safety and immunogenicity of the rVSV-ZEBOV vaccine.
  • * The trial established a research platform and trained local staff for future studies.
  • * While efficacy could not be determined due to low case numbers, safety and immunogenicity data are crucial for vaccine licensure.